Measurement of erythrocyte methotrexate polyglutamate levels: Ready for clinical use in rheumatoid arthritis?

Maria I. Danila; Laura B. Hughes; Elizabeth E. Brown; Sarah L. Morgan; Joseph E. Baggott; Donna K. Arnett; S. Louis Bridges

doi:10.1007/s11926-010-0120-3

Measurement of erythrocyte methotrexate polyglutamate levels: Ready for clinical use in rheumatoid arthritis?

Maria I. Danila
, Laura B. Hughes
, Elizabeth E. Brown
, Sarah L. Morgan
, Joseph E. Baggott
, Donna K. Arnett
, S. Louis Bridges

Producción científica: Review article › revisión exhaustiva

29 Citas (Scopus)

Resumen

Methotrexate (MTX) is one of the most commonly prescribed and most effective drugs for the treatment of rheumatoid arthritis (RA). Given the partial response of many patients and the side effect profile of the drug, there is considerable interest in identifying biomarkers to guide MTX therapy in RA. Upon entering cells, MTX is polyglutamated. Measuring MTX polyglutamate (MTX PG) levels in circulating red blood cells has been proposed as an objective measure to help optimize MTX therapy in RA. Data are conflicting with regard to the clinical utility of MTX PG measurements as a predictor of the efficacy or toxicity of lowdose MTX effects in RA. Should large, randomized clinical trials of this assay show consistent, reproducible, long-term correlations between MTX PG levels and efficacy or toxicity, this test could become a prominent tool for clinicians to optimize the use of MTX in treating RA.

Idioma original	English
Páginas (desde-hasta)	342-347
Número de páginas	6
Publicación	Current Rheumatology Reports
Volumen	12
N.º	5
DOI	https://doi.org/10.1007/s11926-010-0120-3
Estado	Published - oct 2010

Nota bibliográfica

Funding Information:
Acknowledgments This work was supported by National Institutes of Health grants 2P60 AR048095-06 (University of Alabama at Birmingham Multidisciplinary Clinical Research Center, R. P. Kimberly, principal investigator) and the MCRC Project 1 (D. K. Arnett, principal investigator).

Financiación

Acknowledgments This work was supported by National Institutes of Health grants 2P60 AR048095-06 (University of Alabama at Birmingham Multidisciplinary Clinical Research Center, R. P. Kimberly, principal investigator) and the MCRC Project 1 (D. K. Arnett, principal investigator).

Financiadores	Número del financiador
University of Alabama at Birmingham Multidisciplinary Clinical Research Center
National Institutes of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases	P60AR048095

ASJC Scopus subject areas

Rheumatology

Acceder al documento

10.1007/s11926-010-0120-3

Otros archivos y enlaces

Citar esto

@article{e3ebe8b55d754a0581ede4c8d51c538f,

title = "Measurement of erythrocyte methotrexate polyglutamate levels: Ready for clinical use in rheumatoid arthritis?",

abstract = "Methotrexate (MTX) is one of the most commonly prescribed and most effective drugs for the treatment of rheumatoid arthritis (RA). Given the partial response of many patients and the side effect profile of the drug, there is considerable interest in identifying biomarkers to guide MTX therapy in RA. Upon entering cells, MTX is polyglutamated. Measuring MTX polyglutamate (MTX PG) levels in circulating red blood cells has been proposed as an objective measure to help optimize MTX therapy in RA. Data are conflicting with regard to the clinical utility of MTX PG measurements as a predictor of the efficacy or toxicity of lowdose MTX effects in RA. Should large, randomized clinical trials of this assay show consistent, reproducible, long-term correlations between MTX PG levels and efficacy or toxicity, this test could become a prominent tool for clinicians to optimize the use of MTX in treating RA.",

keywords = "Methotrexate, Polyglutamates, Rheumatoid arthritis",

author = "Danila, \{Maria I.\} and Hughes, \{Laura B.\} and Brown, \{Elizabeth E.\} and Morgan, \{Sarah L.\} and Baggott, \{Joseph E.\} and Arnett, \{Donna K.\} and Bridges, \{S. Louis\}",

note = "Funding Information: Acknowledgments This work was supported by National Institutes of Health grants 2P60 AR048095-06 (University of Alabama at Birmingham Multidisciplinary Clinical Research Center, R. P. Kimberly, principal investigator) and the MCRC Project 1 (D. K. Arnett, principal investigator).",

year = "2010",

month = oct,

doi = "10.1007/s11926-010-0120-3",

language = "English",

volume = "12",

pages = "342--347",

number = "5",

}

TY - JOUR

T1 - Measurement of erythrocyte methotrexate polyglutamate levels

T2 - Ready for clinical use in rheumatoid arthritis?

AU - Danila, Maria I.

AU - Hughes, Laura B.

AU - Brown, Elizabeth E.

AU - Morgan, Sarah L.

AU - Baggott, Joseph E.

AU - Arnett, Donna K.

AU - Bridges, S. Louis

N1 - Funding Information: Acknowledgments This work was supported by National Institutes of Health grants 2P60 AR048095-06 (University of Alabama at Birmingham Multidisciplinary Clinical Research Center, R. P. Kimberly, principal investigator) and the MCRC Project 1 (D. K. Arnett, principal investigator).

PY - 2010/10

Y1 - 2010/10

N2 - Methotrexate (MTX) is one of the most commonly prescribed and most effective drugs for the treatment of rheumatoid arthritis (RA). Given the partial response of many patients and the side effect profile of the drug, there is considerable interest in identifying biomarkers to guide MTX therapy in RA. Upon entering cells, MTX is polyglutamated. Measuring MTX polyglutamate (MTX PG) levels in circulating red blood cells has been proposed as an objective measure to help optimize MTX therapy in RA. Data are conflicting with regard to the clinical utility of MTX PG measurements as a predictor of the efficacy or toxicity of lowdose MTX effects in RA. Should large, randomized clinical trials of this assay show consistent, reproducible, long-term correlations between MTX PG levels and efficacy or toxicity, this test could become a prominent tool for clinicians to optimize the use of MTX in treating RA.

AB - Methotrexate (MTX) is one of the most commonly prescribed and most effective drugs for the treatment of rheumatoid arthritis (RA). Given the partial response of many patients and the side effect profile of the drug, there is considerable interest in identifying biomarkers to guide MTX therapy in RA. Upon entering cells, MTX is polyglutamated. Measuring MTX polyglutamate (MTX PG) levels in circulating red blood cells has been proposed as an objective measure to help optimize MTX therapy in RA. Data are conflicting with regard to the clinical utility of MTX PG measurements as a predictor of the efficacy or toxicity of lowdose MTX effects in RA. Should large, randomized clinical trials of this assay show consistent, reproducible, long-term correlations between MTX PG levels and efficacy or toxicity, this test could become a prominent tool for clinicians to optimize the use of MTX in treating RA.

KW - Methotrexate

KW - Polyglutamates

KW - Rheumatoid arthritis

UR - https://www.scopus.com/pages/publications/78149471358

UR - https://www.scopus.com/pages/publications/78149471358#tab=citedBy

U2 - 10.1007/s11926-010-0120-3

DO - 10.1007/s11926-010-0120-3

M3 - Review article

C2 - 20665136

AN - SCOPUS:78149471358

SN - 1523-3774

VL - 12

SP - 342

EP - 347

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

IS - 5

ER -

Measurement of erythrocyte methotrexate polyglutamate levels: Ready for clinical use in rheumatoid arthritis?

Resumen

Nota bibliográfica

Financiación

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto